LON:GENI

GENinCode Interim Earnings Report

GENinCode logo
GBX 1 +0.05 (+5.26%)
As of 06/24/2026 12:23 PM Eastern

GENinCode EPS Results

Actual EPS
-GBX 1.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GENinCode Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GENinCode Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GENinCode Earnings Headlines

AIM Market Roundup: Marechale Capital, Genincode, Boohoo
GENinCode slumps after it reprices options
Read this warning immediately
Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
AIM Market Roundup: Phoenix Copper, Pipehawk, Genincode
See More GENinCode Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GENinCode? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GENinCode and other key companies, straight to your email.

About GENinCode

GENinCode (LON:GENI) is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U. GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.

View GENinCode Profile